Immunotherapy Motolimod Fails to Improve Survival in Ovarian Cancer

The addition of the immune therapy motolimod to pegylated liposomal doxorubicin failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Gynecologic Cancers News Ovarian Cancer Conferences/SGO 2017 Source Type: news